Xanthine oxidase inhibitors in heart failure: where do we go from here?
about
Antioxidants in Cardiovascular Therapy: Panacea or False Hope?Uric acid predicts mortality and ischaemic stroke in subjects with diastolic dysfunction: the Tromsø Study 1994-2013Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studiesSelecting heart failure patients for metabolic interventions.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.Metformin and ageing: improving ageing outcomes beyond glycaemic control.
P2860
Xanthine oxidase inhibitors in heart failure: where do we go from here?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@ast
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@en
type
label
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@ast
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@en
prefLabel
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@ast
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@en
P2860
P1433
P1476
Xanthine oxidase inhibitors in heart failure: where do we go from here?
@en
P2093
Joshua M Hare
Leonardo Tamariz
P2860
P304
P356
10.1161/CIRCULATIONAHA.115.016379
P407
P577
2015-04-14T00:00:00Z